Politico has obtained the draft intellectual property chapter draft, a central component of the Trans Pacific Partnership trade agreement that now being negotiated on Guam. Obama seems to be putting a lot of effort trying to include language that would provide a big windfall for big pharmaceutical corporations, to the detriment of patients and healthcare systems (including Medicare and Medicaid) that would be charged inflated prices for drugs.
Leaked: What's in Obama's trade deal
Is the White House going to bat for Big Pharma worldwide?
By Michael Grunwald
A recent draft of the Trans-Pacific Partnership free-trade deal would give U.S. pharmaceutical firms unprecedented protections against competition from cheaper generic drugs, possibly transcending the patent protections in U.S. law.
POLITICO has obtained a draft copy of TPP’s intellectual property chapter as it stood on May 11, at the start of the latest negotiating round in Guam. While U.S. trade officials would not confirm the authenticity of the document, they downplayed its importance, emphasizing that the terms of the deal are likely to change significantly as the talks enter their final stages. Those terms are still secret, but the public will get to see them once the twelve TPP nations reach a final agreement and President Obama seeks congressional approval.
Still, the draft chapter will provide ammunition for critics who have warned that TPP’s protections for pharmaceutical companies could dump trillions of dollars of additional health care costs on patients, businesses and governments around the Pacific Rim. The highly technical 90-page document, cluttered with objections from other TPP nations, shows that U.S. negotiators have fought aggressively and, at least until Guam, successfully on behalf of Big Pharma.
“The draft text includes provisions that could make it extremely tough for generics to challenge brand-name pharmaceuticals abroad. Those provisions could also help block copycats from selling cheaper versions of the expensive cutting-edge drugs known as “biologics” inside the U.S., restricting treatment for American patients while jacking up Medicare and Medicaid costs for American taxpayers.
There’s very little distance between what Pharma wants and what the U.S. is demanding,” said Rohat Malpini, director of policy for Doctors Without Borders.
Please take a few minutes to read the whole linked piece.
“It would be a dramatic departure from U.S. law, and it would put a real crimp in the ability of less expensive drugs to get to market,” said K.J. Hertz, a lobbyist for AARP. “People are going to look at this very closely in Congress.”
Why would the other countries agree to this unless Obama was offering juicy enticements? What is the US giving up in return?
Obamacare was also crafted in a way that leaves Big Pharma's high drug prices inside the US essentially unscathed. President Obama seems to have an affinity for Big Pharma.